Effects of brentuximab vedotin injection: A Synthesis of Findings from 7 Studies

  1. Home
  2. Effects of brentuximab vedotin injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of brentuximab vedotin injection: A Synthesis of Findings from 7 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of brentuximab vedotin injection: A Synthesis of Findings from 7 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Brentuximab vedotin has shown effectiveness and safety in treating certain types of cancer, including CD30-positive peripheral T-cell lymphoma and Hodgkin lymphoma. 1 The ECHELON-2 trial demonstrated that brentuximab vedotin combined with A+CHP significantly prolonged progression-free survival compared to CHOP therapy for CD30-positive peripheral T-cell lymphoma.

Brentuximab vedotin plus nivolumab has been shown to be a safe and effective treatment option for older patients or those ineligible for standard chemotherapy for Hodgkin lymphoma. 3 The ACCRU trial found that this combination therapy exhibited good response rates with a tolerable safety profile.

Brentuximab vedotin has also been shown to be effective in treating relapsed or refractory classical Hodgkin lymphoma. 2 A study showed that brentuximab vedotin in combination with ifosfamide, carboplatin, and etoposide provided safety and effectiveness in patients with relapsed or refractory classical Hodgkin lymphoma.

In patients with CD30-positive peripheral T-cell lymphoma who received brentuximab vedotin plus CHP, performing hematopoietic stem cell transplantation after achieving complete remission led to a prolonged progression-free survival. 5 The study found that patients who underwent hematopoietic stem cell transplantation had a significantly longer progression-free survival compared to those who did not.

Brentuximab vedotin is an antibody-drug conjugate, and its effectiveness may be influenced by the ratio of antibody to drug. 6 A study suggested that ADCs with a lower antibody-to-drug ratio exhibited slower clearance and demonstrated greater therapeutic effects.

Brentuximab vedotin has been shown to be effective in treating relapsed or refractory CD30-positive Hodgkin lymphoma. 4 A study found that brentuximab vedotin achieved a response rate of 60.4% in 240 patients with a median response duration of 8.4 months. Additionally, patients who received hematopoietic stem cell transplantation after brentuximab vedotin had a significantly prolonged progression-free survival.

Benefits and Risks

Benefit Summary

Brentuximab vedotin has shown to be effective in treating certain types of cancer, including CD30-positive peripheral T-cell lymphoma and Hodgkin lymphoma. It can be used as a single agent or in combination with other treatments. Brentuximab vedotin may help shrink tumors or slow down the progression of the disease.

Risk Summary

Brentuximab vedotin can cause side effects. The most common side effects include fatigue, nausea, vomiting, diarrhea, constipation, rash, fever, chills, and others. More serious side effects include nerve damage, lung inflammation, and liver damage.

Comparison Between Studies

Commonalities in Studies

All of these studies suggest that brentuximab vedotin shows effectiveness and safety in treating specific types of cancer.

Differences Between Studies

These studies differ in the type of cancer they targeted, treatment regimens, and study designs. For instance, the ECHELON-2 trial was a phase 3 trial that evaluated brentuximab vedotin in combination with chemotherapy for patients with CD30-positive peripheral T-cell lymphoma. The ACCRU trial was a phase 2 trial investigating brentuximab vedotin in combination with nivolumab for patients with Hodgkin lymphoma who were older or ineligible for standard chemotherapy. The results of these studies suggest that brentuximab vedotin is a promising treatment option for various cancers.

Consistency and Contradictions in Results

The results of these studies suggest that brentuximab vedotin is a promising treatment option for a range of cancers. However, all of these studies indicate that further research is required to better understand the effects of brentuximab vedotin.

Important Considerations for Real-World Applications

While brentuximab vedotin has been shown to be effective in treating certain types of cancer, not everyone will benefit from this drug. It is essential to discuss the risks and benefits of brentuximab vedotin with your doctor before undergoing treatment.

Limitations of Current Research

All of these studies suggest that additional research is needed to further understand the effects of brentuximab vedotin. More research is needed to determine whether brentuximab vedotin is the right treatment for specific types of cancer.

Future Research Directions

Future studies should examine the effects of brentuximab vedotin across different cancer types, treatment regimens, and patient populations. Research is also needed to investigate the long-term effects and safety of brentuximab vedotin.

Conclusion

Brentuximab vedotin has shown to be effective in treating certain types of cancer, including CD30-positive peripheral T-cell lymphoma and Hodgkin lymphoma. It can be used as a single agent or in combination with other treatments. It is important to discuss the risks and benefits of brentuximab vedotin with your doctor before undergoing treatment.

Literature analysis of 7 papers
Positive Content
7
Neutral Content
0
Negative Content
0
Article Type
2
1
1
0
7
1.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Author: HorwitzSteven, O'ConnorOwen A, ProBarbara, IllidgeTim, FanaleMichelle, AdvaniRanjana, BartlettNancy L, ChristensenJacob Haaber, MorschhauserFranck, Domingo-DomenechEva, RossiGiuseppe, KimWon Seog, FeldmanTatyana, LennardAnne, BeladaDavid, IllésÁrpád, TobinaiKensei, TsukasakiKunihiro, YehSu-Peng, ShustovAndrei, HüttmannAndreas, SavageKerry J, YuenSam, IyerSwaminathan, ZinzaniPier Luigi, HuaZhaowei, LittleMeredith, RaoShangbang, WooleryJoseph, ManleyThomas, TrümperLorenz,

T-cell lymphoma treatment
None mentioned

This study compared the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.

Author: LynchRyan C, CassadayRyan D, SmithStephen D, FrommJonathan R, CowanAndrew J, WarrenEdus H, ShadmanMazyar S, ShustovAndrei, TillBrian G, UjjaniChaitra S, LibbyEdward N, PhilipMary, CoyeHilary, MartinoChristen N, BharkSandra L, MorrisKarolyn, RasmussenHeather, BehniaSanaz, VoutsinasJenna, GopalAjay K

Hodgkin lymphoma treatment

This study aimed to assess the safety and activity of dose-dense brentuximab vedotin combined with ifosfamide, carboplatin, and etoposide (BV-ICE) chemotherapy in second-line treatment of classical Hodgkin lymphoma.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

3.

Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.

Author: ChesonBruce D, BartlettNancy L, LaPlantBetsy, LeeHun J, AdvaniRanjana J, ChristianBeth, DiefenbachCatherine S, FeldmanTatyana A, AnsellStephen M

Hodgkin lymphoma treatment

Hodgkin lymphoma is a cancer that can be cured. However, older patients often have a lower response rate to treatment and worse outcomes. Brentuximab vedotin and nivolumab are medications used to treat relapsed or refractory Hodgkin lymphoma. This study aims to evaluate the safety and effectiveness of these medications in older patients with Hodgkin lymphoma and in younger patients who are not suitable for standard treatment.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

4.

Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.

Author: PerrotAurore, MonjanelHélène, BouabdallahRéda, QuittetPhilippe, SarkozyClémentine, BernardMarc, StamatoullasAspasia, BorelCécile, BouabdallahKrimo, Nicolas-VirelizierEmmanuelle, FournierMarion, MorschhauserFranck, BricePauline,

Brentuximab vedotin
Hodgkin lymphoma treatment
Hematological toxicity
Peripheral neuropathy

Brentuximab vedotin, a CD30-directed antibody-drug conjugate, demonstrated efficacy and manageable toxicity in treating refractory/relapsed Hodgkin lymphoma in 240 patients. The median response duration was 8.4 months, with a median progression-free survival of 6.8 months. Most patients experienced short-term responses, highlighting the need for rapid consideration of high-dose therapy with stem cell transplantation for responders.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

5.

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.

Author: SavageKerry J, HorwitzSteven M, AdvaniRanjana, ChristensenJacob Haaber, Domingo-DomenechEva, RossiGiuseppe, MorschhauserFranck, AlpdoganOnder, SuhCheolwon, TobinaiKensei, ShustovAndrei, TrnenyMarek, YuenSam, ZinzaniPier Luigi, TrümperLorenz, IlidgeTim, O'ConnorOwen A, ProBarbara, MiaoHarry, BunnVeronica, FentonKeenan, FanaleMichelle, PuhlmannMarkus, IyerSwaminathan

Improved PFS
Improved survival

This exploratory subgroups analysis evaluated the impact of consolidative stem cell transplant (SCT) on progression-free survival in patients with CD30+ PTCL. The data support the consideration of SCT in patients who achieve complete response following treatment with brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Interventions for mycosis fungoides.

Author: ValipourArash, JägerManuel, WuPeggy, SchmittJochen, BunchCharles, WeberschockTobias

MF treatment

This Cochrane Review updates a 2012 review on mycosis fungoides (MF), a type of cutaneous T-cell lymphoma. The update assesses new trials, including those investigating novel interventions. Several therapies are available, but they may only induce temporary clinical remission.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.